Golimumab  	Golimumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
psoriatic  	psoriatic  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
golimumab  	golimumab  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
psoriatic  	psoriatic  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
( 	( 	 -LRB-	O
PsA 	PsA 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
data  	data  	 NNS	I-NP
were  	were  	 VBD	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
randomised  	randomised  	 VBD	B-NP
controlled  	controlled  	 VBN	I-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
:  	:  	 :	O
GO-REVEAL 	GO-REVEAL 	 NNP	O
)  	)  	 -RRB-	O
that  	that  	 IN	O
compared  	compared  	 VBN	O
golimumab  	golimumab  	 VBN	O
with  	with  	 IN	O
placebo  	placebo  	 NN	O
for  	for  	 IN	O
treating  	treating  	 VBG	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
active  	active  	 JJ	O
and  	and  	 CC	O
progressive  	progressive  	 JJ	B-NP
PsA  	PsA  	 NN	I-NP
who  	who  	 WP	O
were  	were  	 VBD	O
symptomatic  	symptomatic  	 VBN	O
despite  	despite  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
previous  	previous  	 JJ	O
disease-modifying  	disease-modifying  	 JJ	O
antirheumatic  	antirheumatic  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
or  	or  	 CC	O
non-steroidal  	non-steroidal  	 JJ	B-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs 	drugs 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
14-week  	14-week  	 CD	O
data  	data  	 NNS	O
showed  	showed  	 VBD	O
that 	that 	 IN	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
golimumab  	golimumab  	 CD	B-NP
50  	50  	 CD	O
mg  	mg  	 NNS	B-NP
significantly  	significantly  	 RB	O
improved  	improved  	 VBN	O
joint  	joint  	 JJ	O
disease  	disease  	 NN	B-NP
response  	response  	 NN	I-NP
as  	as  	 IN	O
measured  	measured  	 VBN	O
by  	by  	 IN	O
American  	American  	 NNP	O
College  	College  	 NNP	O
of  	of  	 IN	O
Rheumatology  	Rheumatology  	 NNP	B-NP
( 	( 	 -LRB-	O
ACR 	ACR 	 NNP	B-NP
)  	)  	 -RRB-	O
20  	20  	 CD	O
[ 	[ 	 -LRB-	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
( 	( 	 -LRB-	O
RR 	RR 	 NNP	B-NP
)  	)  	 -RRB-	O
5.73 	5.73 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
( 	( 	 -LRB-	O
CI 	CI 	 NNP	B-NP
)  	)  	 -RRB-	O
3.24  	3.24  	 CD	O
to  	to  	 TO	O
10.56 	10.56 	 CD	O
]  	]  	 -RRB-	O
and  	and  	 CC	O
Psoriatic  	Psoriatic  	 NNP	B-NP
Arthritis  	Arthritis  	 NNP	I-NP
Response  	Response  	 NNP	I-NP
Criteria  	Criteria  	 NNP	I-NP
( 	( 	 -LRB-	O
PsARC 	PsARC 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
3.45 	3.45 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
2.49  	2.49  	 CD	O
to  	to  	 TO	O
4.87 	4.87 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
skin  	skin  	 NN	O
disease  	disease  	 NN	O
response  	response  	 NN	O
as  	as  	 IN	O
measured  	measured  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Psoriasis  	Psoriasis  	 NNP	B-NP
Area  	Area  	 NNP	I-NP
and  	and  	 CC	I-NP
Severity  	Severity  	 NNP	I-NP
Index  	Index  	 NNP	I-NP
( 	( 	 -LRB-	O
PASI 	PASI 	 NNP	B-NP
)  	)  	 -RRB-	O
75  	75  	 CD	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
15.95 	15.95 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
4.62  	4.62  	 NNP	O
to  	to  	 TO	O
59.11 	59.11 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
24-week  	24-week  	 JJ	O
absolute  	absolute  	 JJ	O
data  	data  	 NNS	O
showed  	showed  	 VBD	O
that  	that  	 IN	O
these  	these  	 DT	O
treatment  	treatment  	 NN	B-NP
benefits  	benefits  	 NNS	I-NP
were  	were  	 VBD	O
maintained 	maintained 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
functional  	functional  	 JJ	B-NP
status  	status  	 NN	I-NP
as  	as  	 IN	O
measured  	measured  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Health  	Health  	 NNP	B-NP
Assessment  	Assessment  	 NNP	I-NP
Questionnaire  	Questionnaire  	 NNP	I-NP
( 	( 	 -LRB-	O
HAQ 	HAQ 	 NNP	B-NP
)  	)  	 -RRB-	O
change  	change  	 NN	O
from  	from  	 IN	O
baseline  	baseline  	 NN	B-NP
at  	at  	 IN	O
24  	24  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
-0.33 	-0.33 	 NNP	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
open-label  	open-label  	 JJ	B-NP
extension  	extension  	 NN	I-NP
data  	data  	 NNS	I-NP
showed  	showed  	 VBD	O
that  	that  	 IN	O
these  	these  	 DT	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
were  	were  	 VBD	O
also  	also  	 RB	O
maintained  	maintained  	 VBN	O
at  	at  	 IN	O
52  	52  	 CD	O
and  	and  	 CC	O
104  	104  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
PASI  	PASI  	 NNP	B-NP
50  	50  	 CD	O
and  	and  	 CC	O
PASI  	PASI  	 NNP	B-NP
90  	90  	 CD	O
at  	at  	 IN	O
14  	14  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
all  	all  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
PASI  	PASI  	 NNP	B-NP
outcomes  	outcomes  	 NNS	I-NP
at  	at  	 IN	O
24  	24  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
were  	were  	 VBD	O
not  	not  	 RB	O
performed  	performed  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
intention-to-treat  	intention-to-treat  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
analyses  	analyses  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
24-week  	24-week  	 CD	O
data  	data  	 NNS	O
were  	were  	 VBD	O
less  	less  	 RBR	O
robust 	robust 	 JJ	O
,  	,  	 ,	O
failing  	failing  	 VBG	O
to  	to  	 TO	O
adjust  	adjust  	 VB	O
for  	for  	 IN	O
treatment  	treatment  	 NN	B-NP
contamination  	contamination  	 NN	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
patient  	patient  	 JJ	O
crossover  	crossover  	 NN	B-NP
at  	at  	 IN	O
week  	week  	 NN	B-NP
16 	16 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
conducted  	conducted  	 VBD	O
a  	a  	 DT	O
mixed  	mixed  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
comparison  	comparison  	 NN	I-NP
( 	( 	 -LRB-	O
MTC 	MTC 	 NNP	B-NP
)  	)  	 -RRB-	O
analysis 	analysis 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
considered  	considered  	 VBD	O
the  	the  	 DT	O
assumption  	assumption  	 NN	O
of  	of  	 IN	O
exchangeability  	exchangeability  	 NN	B-NP
between  	between  	 IN	O
the  	the  	 DT	O
trials  	trials  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
MTC  	MTC  	 NNP	B-NP
analysis  	analysis  	 NN	I-NP
to  	to  	 TO	O
be  	be  	 VB	O
acceptable 	acceptable 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
statistical  	statistical  	 JJ	B-NP
approach  	approach  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
MTC  	MTC  	 NNP	B-NP
analysis  	analysis  	 NN	I-NP
to  	to  	 TO	O
be  	be  	 VB	O
reliable 	reliable 	 JJ	O
.  	.  	 .	O
Regarding  	Regarding  	 VBG	O
the  	the  	 DT	O
safety  	safety  	 NN	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
golimumab 	golimumab 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
failed  	failed  	 VBD	O
to  	to  	 TO	O
provide  	provide  	 VB	O
longer-term  	longer-term  	 JJ	B-NP
data  	data  	 NNS	I-NP
or  	or  	 CC	O
to  	to  	 TO	O
consider  	consider  	 VB	O
adverse  	adverse  	 JJ	O
event  	event  	 NN	B-NP
data  	data  	 NNS	I-NP
of  	of  	 IN	I-NP
golimumab  	golimumab  	 NN	I-NP
from  	from  	 IN	O
controlled  	controlled  	 JJ	O
studies  	studies  	 NNS	O
in  	in  	 IN	O
other  	other  	 JJ	O
conditions 	conditions 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
and  	and  	 CC	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis 	spondylitis 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
adverse  	adverse  	 JJ	O
effect  	effect  	 NN	B-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	I-NP
golimumab  	golimumab  	 NN	I-NP
appears  	appears  	 VBZ	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
other  	other  	 JJ	O
anti-tumour  	anti-tumour  	 JJ	B-NP
necrosis  	necrosis  	 JJ	I-NP
factor  	factor  	 NN	I-NP
( 	( 	 -LRB-	O
TNF 	TNF 	 NNP	B-NP
)  	)  	 -RRB-	O
agents 	agents 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
longer-term  	longer-term  	 JJ	B-NP
safety  	safety  	 NN	I-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	I-NP
golimumab  	golimumab  	 NN	I-NP
remains  	remains  	 VBZ	O
uncertain 	uncertain 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
presented  	presented  	 VBD	O
a  	a  	 DT	O
decision  	decision  	 NN	B-NP
model  	model  	 NN	I-NP
to  	to  	 TO	O
compare  	compare  	 VB	O
etanercept 	etanercept 	 NNS	B-NP
,  	,  	 ,	O
infliximab 	infliximab 	 NN	B-NP
,  	,  	 ,	O
golimumab  	golimumab  	 NN	B-NP
and  	and  	 CC	O
adalimumab  	adalimumab  	 FW	B-NP
versus  	versus  	 FW	O
palliative  	palliative  	 FW	B-NP
care  	care  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
PsA 	PsA 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
model 	model 	 NN	I-NP
,  	,  	 ,	O
73 	73 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cohort  	cohort  	 NN	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
assumed  	assumed  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
significant  	significant  	 JJ	O
psoriasis  	psoriasis  	 NNS	B-NP
( 	( 	 -LRB-	O
>  	>  	 CD	O
3 	3 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
body  	body  	 NN	O
surface  	surface  	 NN	O
area 	area 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Estimates  	Estimates  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
anti-TNF  	anti-TNF  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
PsARC 	PsARC 	 NNP	B-NP
,  	,  	 ,	O
HAQ  	HAQ  	 NNP	B-NP
change  	change  	 NN	I-NP
and  	and  	 CC	O
PASI  	PASI  	 NNP	B-NP
change  	change  	 NN	I-NP
were  	were  	 VBD	O
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
an  	an  	 DT	O
MTC  	MTC  	 NNP	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	I-NP
RCT  	RCT  	 NNP	I-NP
data 	data 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
failed  	failed  	 VBD	O
to  	to  	 TO	O
calculate  	calculate  	 VB	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratios  	ratios  	 NNS	I-NP
( 	( 	 -LRB-	O
ICERs 	ICERs 	 NNP	B-NP
)  	)  	 -RRB-	O
correctly  	correctly  	 RB	O
by  	by  	 IN	O
comparing  	comparing  	 VBG	B-NP
golimumab  	golimumab  	 NN	I-NP
with  	with  	 IN	O
palliative  	palliative  	 JJ	B-NP
care  	care  	 NN	I-NP
instead  	instead  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
cost-effective  	cost-effective  	 JJ	B-NP
alternative  	alternative  	 NN	I-NP
( 	( 	 -LRB-	O
etanercept 	etanercept 	 LS	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Despite  	Despite  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
claim  	claim  	 NN	O
that  	that  	 IN	O
golimumab  	golimumab  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
cost-effective  	cost-effective  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
option 	option 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
own  	own  	 JJ	O
model  	model  	 NN	O
showed  	showed  	 VBD	O
that  	that  	 DT	O
golimumab  	golimumab  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
cost-effective  	cost-effective  	 JJ	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
other  	other  	 JJ	O
biologics  	biologics  	 NN	B-NP
when  	when  	 WRB	O
the  	the  	 DT	O
ICERs  	ICERs  	 NNS	B-NP
are  	are  	 VBP	O
correctly  	correctly  	 RB	O
calculated 	calculated 	 VBN	O
.  	.  	 .	O
None  	None  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
sensitivity  	sensitivity  	 NN	B-NP
analyses  	analyses  	 NNS	I-NP
carried  	carried  	 VBD	O
out  	out  	 RP	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
or  	or  	 CC	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
regarding  	regarding  	 VBG	B-NP
uncertainty  	uncertainty  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
effectiveness 	effectiveness 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
acquisition  	acquisition  	 NN	O
and  	and  	 CC	O
administration  	administration  	 NN	B-NP
cost  	cost  	 NN	I-NP
of  	of  	 IN	O
drugs 	drugs 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
cost  	cost  	 NN	O
of  	of  	 IN	O
treating  	treating  	 VBG	B-NP
psoriasis  	psoriasis  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
utility  	utility  	 NN	B-NP
functions  	functions  	 NNS	I-NP
estimated  	estimated  	 VBN	O
to  	to  	 TO	O
generate  	generate  	 VB	O
health  	health  	 NN	B-NP
outcomes  	outcomes  	 NNS	I-NP
changed  	changed  	 VBD	O
this  	this  	 DT	O
conclusion 	conclusion 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
key  	key  	 JJ	B-NP
area  	area  	 NN	I-NP
in  	in  	 IN	O
determining  	determining  	 VBG	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
anti-TNF  	anti-TNF  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
is  	is  	 VBZ	O
whether  	whether  	 IN	O
they  	they  	 PRP	O
should  	should  	 MD	O
be  	be  	 VB	O
treated  	treated  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
class 	class 	 NN	O
.  	.  	 .	O
If  	If  	 IN	O
all  	all  	 DT	O
anti-TNF  	anti-TNF  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
are  	are  	 VBP	O
considered  	considered  	 VBN	O
equally  	equally  	 RB	O
effective  	effective  	 JJ	O
then  	then  	 RB	O
etanercept 	etanercept 	 JJ	O
,  	,  	 ,	O
adalimumab  	adalimumab  	 NN	B-NP
and  	and  	 CC	O
golimumab  	golimumab  	 NNS	B-NP
have  	have  	 VBP	O
very  	very  	 RB	O
nearly  	nearly  	 RB	O
equal  	equal  	 JJ	O
costs  	costs  	 NNS	O
and  	and  	 CC	O
equal  	equal  	 JJ	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-years  	life-years  	 NN	I-NP
( 	( 	 -LRB-	O
QALYs 	QALYs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
all  	all  	 RB	O
have  	have  	 VB	O
an  	an  	 DT	O
ICER  	ICER  	 NNP	B-NP
of  	of  	 IN	O
about  	about  	 IN	O
£  	£  	 CD	O
15,000  	15,000  	 CD	O
per  	per  	 FW	O
QALY  	QALY  	 FW	B-NP
versus  	versus  	 FW	O
palliative  	palliative  	 FW	B-NP
care 	care 	 NN	I-NP
,  	,  	 ,	O
whereas  	whereas  	 IN	O
infliximab  	infliximab  	 NN	B-NP
with  	with  	 IN	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
acquisition  	acquisition  	 NN	B-NP
cost  	cost  	 NN	I-NP
is  	is  	 VBZ	O
dominated  	dominated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
biologics 	biologics 	 NN	B-NP
.  	.  	 .	O
